Provider Briefing: Estradiol/Norethindrone/Relugolix (Myfembree) Availability in 2026

If your patients are reporting difficulty filling their Estradiol/Norethindrone/Relugolix (Myfembree) prescriptions, you're not alone in hearing this. While the medication is not in a formal FDA-reported shortage, access challenges persist due to the drug's specialty status, cost, and insurance landscape.

This briefing provides an overview of the current availability picture, prescribing implications, cost and access considerations, and tools to help your patients get the medication they need.

Current Shortage Status and Timeline

As of early 2026, Myfembree is not on the FDA's drug shortage list. Myovant Sciences continues to manufacture and distribute the medication without reported supply interruptions.

Key timeline:

• May 2021: FDA approval for heavy menstrual bleeding associated with uterine fibroids
• August 2023: FDA approval expanded to moderate to severe pain associated with endometriosis
• Late 2025–2026: Patent exclusivities beginning to expire; potential for generic entry, though no generic has been approved as of March 2026

The access difficulties patients experience are structural — related to pharmacy stocking practices, insurance requirements, and high acquisition cost — rather than supply-driven.

Prescribing Implications

Understanding the access barriers can help you set appropriate patient expectations and streamline the prescribing process.

Prior Authorization Is Nearly Universal

Virtually all commercial insurance plans and many managed Medicaid plans require prior authorization for Myfembree. Some plans also impose step therapy requirements, typically requiring documented failure of or intolerance to:

• Hormonal contraceptives (oral or IUD-based)
• Tranexamic acid (for fibroid-related bleeding)
• NSAIDs (for endometriosis pain)

Proactive prior authorization — initiated when the prescribing decision is made, rather than after the prescription reaches the pharmacy — can significantly reduce the time to first fill.

Specialty Pharmacy Dispensing

Many insurance plans require or strongly encourage specialty pharmacy dispensing for Myfembree. This can actually work in the patient's favor, as specialty pharmacies reliably stock the medication and have infrastructure for managing prior authorization and copay assistance enrollment. Consider directing prescriptions to the patient's insurance-designated specialty pharmacy when possible.

Dosing and Duration Considerations

Myfembree is prescribed as one tablet daily (Relugolix 40 mg / Estradiol 1 mg / Norethindrone Acetate 0.5 mg). Key prescribing reminders:

• Treatment duration: up to 24 months for both uterine fibroids and endometriosis
• Baseline DXA scan is recommended, with periodic monitoring during treatment (annual for endometriosis; periodic for fibroids)
• Initiate within the first 5 days of a menstrual period
• Non-hormonal contraception required during treatment
• Monitor for mood changes, suicidal ideation, hepatic transaminase elevations, and blood pressure changes

For complete prescribing details, including drug interactions and side effect management, refer to the full prescribing information.

Availability Picture

The practical availability landscape for Myfembree:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Typically do not stock Myfembree on shelves. Will order upon confirmed prescription and insurance approval, usually with 1–2 business day turnaround.
• Specialty pharmacies (CVS Specialty, Accredo, AllianceRx Walgreens, Optum): Routinely stock Myfembree. Best option for reliable, consistent access.
• Independent pharmacies: May be willing to order; some already stock it if they serve a patient population with OB/GYN needs.
• Mail-order specialty: Available through most insurance plans. Good option for patients in areas with limited specialty pharmacy access.

The medication availability tracker at Medfinder for Providers can help your practice identify local pharmacies with current stock.

Cost and Access

Cost remains a significant barrier to Myfembree access. Here's what your patients are likely facing:

Cash Pricing

• Without insurance: $1,300–$1,700/month
• With discount cards: Approximately $1,200–$1,560/month

Insurance Coverage

• Most commercial plans cover Myfembree on specialty or high tiers
• Prior authorization required by nearly all plans
• Step therapy may be required by some plans
• Patient cost with insurance: typically $30–$300+ per fill depending on tier and deductible status

Manufacturer Support Programs

• Myfembree Copay Assistance Program: Eligible commercially insured patients pay as little as $5/month (or $15 for 90-day supply), with up to $5,000 in annual savings. Not available for government-insured patients (Medicare, Medicaid, TRICARE).
• Patient Assistance Program: Available for uninsured or underinsured patients experiencing financial hardship. Contact Myovant patient services for enrollment.

For a comprehensive patient-facing guide on cost reduction, see saving money on Estradiol/Norethindrone/Relugolix.

Tools and Resources for Your Practice

Several tools can help integrate Myfembree prescribing into your workflow more smoothly:

• Medfinder for Providers: Check real-time pharmacy availability for Myfembree and other hard-to-find medications in your patient's area.
• Myfembree HCP Portal: Access prescribing resources, prior authorization forms, and copay card enrollment at myfembreehcp.com.
• Electronic prior authorization: If your EHR supports e-prior authorization, use it to reduce turnaround time from days to hours.

Alternative Treatment Options

When Myfembree is inaccessible or inappropriate for a patient, consider these alternatives:

• Oriahnn (Elagolix/Estradiol/Norethindrone Acetate) — GnRH antagonist with add-back; approved for uterine fibroids only; twice-daily dosing
• Orilissa (Elagolix) — GnRH antagonist without built-in add-back; approved for endometriosis pain; can add separate add-back therapy
• Lupron Depot (Leuprolide Acetate) — Injectable GnRH agonist; used for both fibroids and endometriosis; typically for shorter treatment courses
• Levonorgestrel IUD (Mirena, Liletta) — First-line for heavy menstrual bleeding; does not shrink fibroids but reduces bleeding; long-acting (5–8 years)

A detailed comparison is available in our alternatives guide.

Looking Ahead

Several developments may improve Myfembree access in the coming months:

• Generic entry potential: With patent exclusivities expiring, a generic version could reach the market in 2026, significantly reducing cost and improving pharmacy stocking.
• Expanded payer coverage: As clinical data and real-world evidence accumulate, some plans may reduce prior authorization barriers or move Myfembree to more favorable formulary tiers.
• Growing prescriber familiarity: The 2023 endometriosis indication expansion has broadened the prescribing base, which may drive increased pharmacy stocking over time.

Final Thoughts

Myfembree remains an important treatment option for premenopausal women with symptomatic uterine fibroids and endometriosis. While it is not in formal shortage, the structural access barriers — specialty status, cost, and insurance requirements — are real and affect patient outcomes.

By proactively managing prior authorization, directing prescriptions to specialty pharmacies, and connecting patients with financial assistance programs, you can help minimize treatment delays. Medfinder for Providers is available as a free tool to help your practice navigate medication availability challenges.